Drug of choice for Her 2 Neu positive Breast cancer
**Core Concept**
Her2 neu positive breast cancer is a subtype of breast cancer that overexpresses the human epidermal growth factor receptor 2 (Her2/neu) protein. This overexpression leads to an aggressive tumor growth. The treatment of Her2 neu positive breast cancer involves targeted therapy to inhibit the Her2/neu protein.
**Why the Correct Answer is Right**
Trastuzumab is a monoclonal antibody that specifically targets and binds to the Her2/neu protein, thereby inhibiting its activity and leading to reduced tumor growth. Trastuzumab works by blocking the epidermal growth factor receptor (EGFR) pathway, which is involved in cell proliferation and survival. The binding of trastuzumab to Her2/neu also leads to antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which further contributes to the anti-tumor effect.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because while anthracyclines (e.g., doxorubicin) are a common chemotherapeutic agent used in breast cancer, they are not the drug of choice for Her2 neu positive breast cancer due to their potential cardiotoxicity.
**Option B:** This option is incorrect because while taxanes (e.g., paclitaxel) are used in combination with trastuzumab, they are not the primary treatment for Her2 neu positive breast cancer.
**Option C:** This option is incorrect because while hormone therapy (e.g., tamoxifen) is used in hormone receptor-positive breast cancer, it is not effective in Her2 neu positive breast cancer due to the absence of hormone receptors.
**Clinical Pearl / High-Yield Fact**
Trastuzumab should be used in combination with chemotherapy (e.g., anthracyclines and taxanes) for the treatment of Her2 neu positive breast cancer, as this combination has been shown to improve survival outcomes compared to chemotherapy alone.
**Correct Answer:** C. Trastuzumab